Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection-Reference-Cited by-同舟云学术

Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection

Published:2019-06 Issue:6 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Beccari Mario V.¹,Mogle Bryan T.¹^ORCID,Sidman Eric F.¹²,Mastro Keri A.³,Asiago-Reddy Elizabeth²,Kufel Wesley D.¹²³^ORCID

Affiliation:

1. State University of New York Upstate University Hospital, Syracuse, New York, USA

2. State University of New York Upstate Medical University, Syracuse, New York, USA

3. Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA

Abstract

Limited antiretrovirals are currently available for the management of multidrug-resistant (MDR) HIV-1 infection. Ibalizumab, a recombinant humanized monoclonal antibody, represents the first novel agent for HIV-1 management in over a decade and is the first monoclonal antibody for the treatment of MDR HIV-1 infection in combination with other forms of antiretroviral therapy in heavily treatment-experienced adults who are failing their current antiretroviral regimen.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00110-19

Reference37 articles.

1. Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy

2. OptumRx. 2018. Trogarzo (ibalizumab-uiyk): new orphan drug approval. OptumRx, Irvine, CA.

3. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1

4. Monoclonal Antibodies as Innovative Therapeutics

5. TaiMed Biologics. 2018. Trogarzo (ibalizumab-uiyk): highlights of prescribing information. TaiMed Biologics, Irvine, CA.

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of Ibalizumab for the treatment of HIV-1 infected patients: A systematic review;Global Journal of Health Sciences and Research;2024-08-26

2. Nucleoside Reverse Transcriptase Inhibitors Are the Major Class of HIV Antiretroviral Therapeutics That Induce Neuropathic Pain in Mice;International Journal of Molecular Sciences;2024-08-21

3. Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab;Antiviral Research;2024-08

4. A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV;Journal of Pharmacy Technology;2024-07-27

5. Development of Anti-HIV Therapeutics: From Conventional Drug Discovery to Cutting-Edge Technology;Pharmaceuticals;2024-07-04